Thomas Broeer elected as new BGMA Chairman

Brings more than 20 years of industry experience to the position

The British Generic Manufacturers Association (BGMA) has appointed Thomas Broeer, Managing Director of Kent Pharmaceuticals, as its new Chairman for the next two years.

He replaces Kim Innes, a director with Teva, who will continue for a further year as Vice-Chairwoman of the association.

Broeer brings more than 20 years of international pharmaceutical business management experience to the BGMA role, working both within the generic and branded industries. Before joining Kent Pharmaceuticals earlier this year, he had previously held senior management roles with Mylan in the UK and Germany.

Broeer said: 'There are a number of challenges and issues facing the generics industry as business models evolve, regulations change and new opportunities such as biosimilars emerge. The association has a crucial role in all these and I look forward to playing an important part in representing our views.'

You may also like

Regulatory

BGMA reacts to Sir John Bell's findings on the UK life sciences sector

Reaction from the British Generic Manufacturers Association (BGMA) to Sir John Bell outlining his findings into how the life sciences sector can work with the UK government to provide an even greater economic and societal contribution
Regulatory

Further reaction to the EU referendum result

Comments from British Generic Manufacturers Association and the British Biosimilars Association, and APBI
Regulatory

NHS England publishes authoritative information on biosimilar medicines

Document provides key clinical and non-clinical stakeholders with accessible information on how to support the appropriate use of all biological medicines
Pharmaceutical

DoH and BGMA announce joint generics initiative

Will look at IP, evergreening, patent law, exclusivity and regulation, among other issues
Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Subscribe now